Type III inhibitors of MEK1/2 (trametinib, cobimetinib, and binimetinib) are approved as cancer therapeutics, used in the treatment of melanoma and non–small cell lung cancer patients who have mutations in BRAF, in combination with a BRAF inhibitor. Here, BRAF is linked to melanoma.